Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | CPS1 | P31327 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678970 | 1.00 | HTR2C (0.52) | HTR2CCPS1FFAR4CACNA1CPTGDR2 | |
| Fumaric Acid SCHEMBL4682321 | 0.94 | HTR2C (0.49) | HTR2CCPS1FFAR4CACNA1CPTGDR2 | |
| Fumaric Acid SCHEMBL4682318 | 0.94 | HTR2C (0.49) | HTR2CCPS1FFAR4CACNA1CPTGDR2 | |
| Fumaric Acid SCHEMBL4682319 | 0.94 | HTR2C (0.49) | HTR2CCPS1FFAR4CACNA1CPTGDR2 | |
| SCHEMBL4681392 | 0.91 | HTR2C (0.50) | HTR2CCPS1ALDH1A1KAT6AHTR2A | |
| SCHEMBL4681396 | 0.91 | HTR2C (0.50) | HTR2CCPS1ALDH1A1KAT6AHTR2A | |
| SCHEMBL4681721 | 0.91 | HTR2C (0.50) | HTR2CCPS1ALDH1A1HTR2A | |
| SCHEMBL4681717 | 0.91 | HTR2C (0.50) | HTR2CCPS1ALDH1A1HTR2A | |
| SCHEMBL4680884 | 0.89 | HTR2C (0.54) | HTR2CCPS1 | |
| SCHEMBL4680891 | 0.89 | HTR2C (0.54) | HTR2CCPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | HTR2C 289/4885CPS1 1551/4885FFAR4 165/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | HTR2C 289/4885CPS1 1551/4885FFAR4 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.